Stocks Health care WVE
NASDAQ · Health careWave Life Sciences Ltd. (WVE)
Wave Life Sciences Ltd. brought in $70.9M of revenue over the twelve months to September 30, 2026. It posted a net loss of $210.5M. In fiscal 2025 capital spending exceeded operating cash flow by $188.2M. At September 30, 2026 it held $197.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 27, 2026.
Key facts about Wave Life Sciences Ltd.
- Net worth
- Wave Life Sciences Ltd. has a market value (market cap) of $663.1M at the latest share price, and shareholders' equity of $401.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $42.7M (-60.5% year on year), with a net loss of $204.4M. Over the 12 months to September 30, 2026: revenue $70.9M, net loss $210.5M.
- Cash flow
- In fiscal 2025 operations used $187.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 27, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Wave Life Sciences Ltd.'s next report is expected around January 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Wave Life Sciences Ltd. does
Wave Life Sciences Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker WVE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $42.7M | -$204.4M | -$1.21 | -$188.2M |
| 2024 | $108.3M | -$97M | -$0.70 | -$152M |
| 2023 | $113.3M | -$57.5M | -$0.54 | -$20.5M |
| 2022 | $3.6M | -$161.8M | -$2.05 | -$129.1M |
| 2021 | $41M | -$122.2M | -$2.36 | -$89.6M |
| 2020 | $20.1M | -$149.9M | -$3.82 | -$117.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where WVE ranks in Health care
Latest SEC filings
What Wave Life Sciences Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 27, 2026Passive stake (5% or more) SCHEDULE 13G
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 73% to $13.2M versus the same quarter last year; diluted EPS -$0.30 versus -$0.32.
- October 27, 2026
- October 14, 2026
- October 14, 2026Proxy statement DEF 14A
- August 11, 2026Activist stake changed SCHEDULE 13D/A
- August 10, 2026Deregistration 15-12G
- August 10, 2026Form POS AM filing POS AM
- August 10, 2026Form POSASR filing POSASR
Insider trades
What the people running Wave Life Sciences Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 8 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Wagner Heidi LDirector | Received as pay | 10,700 | - |
| October 5, 2026 | Henry Christian ODirector | Received as pay | 10,700 | - |
| October 5, 2026 | Rawcliffe AdrianDirector | Received as pay | 10,700 | - |
| October 5, 2026 | Corrigan MarkDirector | Received as pay | 10,700 | - |
| October 5, 2026 | Takanashi KenDirector | Received as pay | 10,700 | - |
| October 5, 2026 | Tan Aik NaDirector | Received as pay | 10,700 | - |
| October 5, 2026 | Verdine Gregory L.Director | Received as pay | 10,700 | - |
| October 5, 2026 | Ra Capital Management, L.P.Director, 10% owner | Received as payindirect | 10,700 | - |
Who owns WVE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13D, may seek influence with 3 related filers | 16.8% | August 11, 2026 |
| Maverick Capital, Ltd.13G, passive with 2 related filers | 5.4% | February 14, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 239 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 26,975,505 | 0 |
| BlackRock, Inc. | 19,202,461 | +5,085,049 |
| GSK plc | 18,245,691 | 0 |
| Maverick Capital Ltd | 10,278,115 | +116,716 |
| Driehaus Capital Management LLC | 5,443,143 | +12,122 |
| Primecap Management Co | 5,354,622 | +521,670 |
| 683 Capital Management, LLC | 4,950,000 | +50,000 |
| Fmr LLC | 4,922,477 | -270,284 |
| State Street Corp | 4,839,317 | +1,165,284 |
| Readystate Asset Management LP | 4,727,139 | new |
| M28 Capital Management LP | 4,588,284 | 0 |
| Geode Capital Management, LLC | 3,869,998 | +290,899 |
| Two Sigma Investments, LP | 3,707,686 | +1,829,571 |
| Algert Global LLC | 2,817,615 | +1,502,026 |
| Qube Research & Technologies Ltd | 2,776,000 | +2,620,076 |
| Squarepoint Ops LLC | 2,541,442 | +1,079,052 |
| Morgan Stanley | 2,422,705 | +1,061,704 |
| Vanguard Portfolio Management LLC | 2,110,751 | +934,544 |
| Pfizer Inc | 1,875,000 | 0 |
| Millennium Management LLC | 1,811,282 | +839,041 |
Insiders
13 insiders reported holding 56,543,508 shares in total, about $190.3M at the last price.
| Holder | Shares |
|---|---|
| Ra Capital Management, L.P.Director, 10% owner | 27,015,02027,015,020 held indirectly |
| GSK plc10% owner | 18,245,69118,245,691 held indirectly |
| Takanashi KenDirector | 9,637,1879,606,408 held indirectly |
| Verdine Gregory L.Director | 476,134 |
| Vargeese ChandraSee Remarks | 408,246 |
| Bolno PaulPresident and CEO, Director | 275,520 |
| Moran KyleChief Financial Officer | 134,385 |
| Wagner Heidi LDirector | 100,560 |
| Corrigan MarkDirector | 68,330 |
| Francis ChrisSee Remarks | 61,867 |
Questions about WVE
What does Wave Life Sciences Ltd. do?
Wave Life Sciences Ltd. is a company in the Health care sector, listed on NASDAQ as WVE. Its shares trade on NASDAQ under the ticker WVE.
What is Wave Life Sciences Ltd.'s net worth?
Wave Life Sciences Ltd. has a market value (market cap) of $663.1M at the latest share price, and shareholders' equity of $401.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Wave Life Sciences Ltd. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $210.5M on revenue of $70.9M.
How much revenue does Wave Life Sciences Ltd. make?
Over the twelve months to September 30, 2026 Wave Life Sciences Ltd. reported revenue of $70.9M.
When did Wave Life Sciences Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 27, 2026. It covers the period to September 30, 2026.
When is Wave Life Sciences Ltd.'s next earnings report?
Wave Life Sciences Ltd.'s next report is expected around January 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare WVE with
Follow WVE
Get an email when Wave Life Sciences Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Wave Life Sciences Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.